Beam Therapeutics Inc. (BEAM) is a Cambridge, Massachusetts-based biotechnology company developing precision genetic medicines using base-editing technology. With the stock trading in the upper $20s and a field of Wall Street analysts setting price targets well above that level, the question of whether BEAM can reach $50 has become central to the debate around the name.
Approximately 15 analyst price targets were reviewed, ranging from a low near $26 to a high of $80. The arithmetic mean of these targets is about $49.38, which rounds to a $50 central target. The view is broadly constructive, with the coverage skewing heavily toward Buy-equivalent ratings; a handful of firms carry more cautious or neutral stances, which explains the wide low-to-high spread.
Among the individual targets, H.C. Wainwright, Guggenheim, and Canaccord Genuity have published some of the highest figures at or near $78 to $80, while Wedbush, Wells Fargo, and Citi cluster in the $65 to $70 area. More cautious desks such as UBS, JonesTrading, Evercore, RBC Capital, and Clear Street carry targets in the upper-$20s to upper-$30s. This divergence reflects genuine disagreement about how far the pipeline can be valued before meaningful clinical and commercial proof arrives, rather than a single uniform consensus.
BEAM's latest verified price sits near $27.23, within a 52-week range of roughly $20.23 to $38.26. Reaching $50 from this level would require about an 84% advance, which qualifies as a very large move. A path to that level would almost certainly require positive clinical data, additional regulatory progress, or a partnership or financing event that materially changes how the market values the pipeline, rather than a small improvement in sentiment alone.
Beam's base-editing platform is differentiated from conventional CRISPR approaches, and the company has multiple programs advancing through development, including BEAM-101 for sickle cell disease (the BEACON trial), BEAM-302 for alpha-1 antitrypsin deficiency, and BEAM-301 for glycogen storage disease type 1a. The FDA's clearance of the investigational new drug application for the BEAM-304 phenylketonuria (PKU) candidate represents a recent regulatory milestone. A heavily bullish analyst posture and a high end of the target range near $80 suggest that some analysts believe successful execution could justify prices well above $50.
Beam remains deeply unprofitable, with analysts modeling roughly $74 million in 2026 revenue—a substantial year-over-year decline reflecting lumpy, milestone-dependent collaboration income—alongside continued per-share losses. Clinical-stage biotechs face binary risks: trial failures, regulatory setbacks, and safety concerns can sharply reset valuations. Beam also competes in gene editing against larger, well-funded players, and any need to raise capital could dilute shareholders. The stock's elevated beta and wide analyst range underscore that the $50 objective is far from assured.
BEAM's 52-week high near $38.26 stands out as a key resistance level and a logical first hurdle on any move toward $50, since the stock has not traded above that zone in the past year. The 200-day moving average near $28 and the 50-day moving average near $26 have acted as short-term reference points, while the 52-week low near $20.23 represents the primary support level. Clearing the prior high would likely be viewed as a necessary technical step before a sustained advance toward $50 becomes plausible.
Most analyst price targets are intended to reflect a roughly 12-month research horizon, though individual firms differ in their assumptions and timeframes. The most relevant upcoming items include Beam's next quarterly earnings report, further BEACON trial readouts, additional regulatory decisions across the pipeline, and any partnership or financing announcements. Changes to analyst revenue and EPS estimates, as well as revisions to individual price targets, will also be important signals of shifting conviction.
For investors who prefer a data-driven overlay to fundamental research, AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. Consider exploring the platform to see how its signals apply to BEAM and the broader market.
The $50 target for Beam Therapeutics reflects the average of a wide-ranging set of analyst price targets spanning roughly $26 to $80, and it requires an advance of about 84% from current levels. A differentiated base-editing platform, an advancing pipeline, and recent regulatory progress support the bullish case, while persistent losses, declining collaboration revenue, clinical risk, and high volatility argue for caution. Given the wide spread between the lowest and highest targets, the $50 figure is best understood as a midpoint of sharply divided opinions rather than a consensus certainty. Investors should watch upcoming clinical data and earnings releases closely, as those events are most likely to determine whether the stock can build a credible path toward the target.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To BEAM | 1D Price Change % | ||
|---|---|---|---|---|
| BEAM | 100% | +2.31% | ||
| CRSP - BEAM | 77% Closely correlated | -0.06% | ||
| EDIT - BEAM | 67% Closely correlated | +7.00% | ||
| NTLA - BEAM | 67% Closely correlated | +6.70% | ||
| PRME - BEAM | 65% Loosely correlated | -7.53% | ||
| RXRX - BEAM | 60% Loosely correlated | +8.10% | ||
More | ||||